Latest on Ultrasound Renal Denervation

Published: 22 June 2022

Views:
7485
Likes:
7

Views:
7485
Likes:
7
Share:

Now Playing
Part 6
Ultrasound Renal Denervation – Patient Perspective, Referral Development
Melvin D Lobo

Up Next

1h 4m 58s

Part 7 | Session 1 ACC 2022 Symposium
Michael Weber, Felix Mahfoud, Ajay J Kirtane, Michael Bloch
59m 32s

Part 7 | Session 2 TCT 2021 Symposium
Chandan Devireddy, Ajay J Kirtane, Felix Mahfoud, Naomi Fisher

4m 2s

Part 1 | Session 1 The Science of Ultrasound Renal Denervation: Introduction Philipp Lurz, Michael Joner, Felix Mahfoud, Andrew Wu

9m 18s

Part 1 | Session 2 Ultrasound Technology – Its Development and Unique Characteristics: Andy Wu Andrew Wu

15m 10s

Part 1 | Session 3 Ultrasound Renal Denervation Preclinical Evidence: Dr Michael Joner Michael Joner

18m 36s

Part 1 | Session 4 RDN Procedure with Ultrasound Technology: Prof Felix Mahfoud Felix Mahfoud

10m 14s

Part 1 | Session 5 Panel Discussion: All Philipp Lurz, Michael Joner, Felix Mahfoud, Andrew Wu

15m 15s

Part 2 | Session 1 The Paradise uRDN System: Dr Andrew Sharp Andrew SP Sharp

9m 57s

Part 2 | Session 2 uRDN Clinical Evidence - What does this mean for the field?: Prof Felix Mahfoud Felix Mahfoud

21m 53s

Part 2 | Session 3 How to build uRDN centre / therapy pathway: Prof Roland Schmieder Roland E Schmieder

19m 35s

Part 3 | Session 1 Introduction and "Ultrasound RDN - Reviewing the Latest Clinical Results" : Atul Pathak Joost Daemen, Atul Pathak, Joachim Weil

11m 41s

Part 3 | Session 2 "Ultrasound RDN - Reviewing the Latest Clinical Results" : Joost Daemen Joost Daemen, Atul Pathak, Joachim Weil

28m 37s

Part 3 | Session 3 "How to build Interventional HTN Therapy/Practice": Joachim Weil Joost Daemen, Atul Pathak, Joachim Weil

5m 12s

Part 4 | Session 1 RADIANCE II Pivotal Trial Ajay J Kirtane

1h 20s

Part 4 | Session 2 Ultrasound Renal Denervation (uRDN) – Leading with Evidence and Preparing for What Comes Next

5m 10s

Part 5 | Session 1 EuroPCR 2022 – Patient-Level Pooled Analysis of RADIANCE-HTN SOLO and TRIO Trials Ajay J Kirtane

4m 44s

Part 5 | Session 2 TCT 2021 – RADIANCE-HTN TRIO 6 months Outcomes vs Sham Procedure for Resistant Hypertension Ajay J Kirtane

16m 20s

Part 5 | Session 3 ACC 2021 – RADIANCE-HTN TRIO Trial Results with Ajay Kirtane Ajay J Kirtane, Harriette Van Spall

5m 47s

Part 5 | Session 4 EuroPCR 2020 – Crossover Results From the RADIANCE-HTN SOLO Trial Ajay J Kirtane

Average (ratings)

No ratings

Your rating

Overview

Ultrasound Renal Denervation (uRDN) is an innovative therapy option for the treatment of uncontrolled hypertension. uRDN therapy is delivered in a minimally invasive procedure that may lower high blood pressure by treating overactive renal nerves with ultrasound energy.

This page provides an overview of uRDN technology and the latest evidence from its associated RADIANCE clinical program.

The PARADISE^TM System is Limited to Investigational Use Only in the United States. Approved for distribution in CE mark countries only.

This educational content is supported by:

What you will learn:

How uRDN works and its potential benefits for patients suffering from uncontrolled hypertension
The clinical evidence supporting uRDN and its implications for the field of hypertension
The process for building a uRDN centre and therapy network

This page is designed for:

Interventional cardiologists
General cardiologists
Hypertension specialists
Nephrologists
Interventional radiologists

More from this programme

Part 1

The Science of uRDN

Understand the science of Ultrasound Renal Denervation (uRDN) and its potential benefits for the treatment of uncontrolled hypertension

5 sessions
The Science of Ultrasound Renal Denervation: Introduction	Watch now
Ultrasound Technology – Its Development and Unique Characteristics: Andy Wu	Watch now
Ultrasound Renal Denervation Preclinical Evidence: Dr Michael Joner	Watch now
RDN Procedure with Ultrasound Technology: Prof Felix Mahfoud	Watch now
Panel Discussion: All	Watch now

Part 2

The Evidence for uRDN

3 sessions
The Paradise uRDN System: Dr Andrew Sharp	Watch now
uRDN Clinical Evidence - What does this mean for the field?: Prof Felix Mahfoud	Watch now
How to build uRDN centre / therapy pathway: Prof Roland Schmieder	Watch now

Part 3

From Proof to Practice – Treating Hypertension With uRDN

3 sessions
Introduction and "Ultrasound RDN - Reviewing the Latest Clinical Results" : Atul Pathak	Watch now
"Ultrasound RDN - Reviewing the Latest Clinical Results" : Joost Daemen	Watch now
"How to build Interventional HTN Therapy/Practice": Joachim Weil	Watch now

Part 4

RADIANCE II Pivotal Trial for Paradise Ultrasound Renal Denervation System in Patients With Hypertension

TCT 2022 Satellite Symposium.

2 sessions
RADIANCE II Pivotal Trial	Watch now
Ultrasound Renal Denervation (uRDN) – Leading with Evidence and Preparing for What Comes Next	Watch now

Part 5

Results From the Latest Clinical Trials

Deep dive into the latest information on the RADIANCE-HTN trials

4 sessions
EuroPCR 2022 – Patient-Level Pooled Analysis of RADIANCE-HTN SOLO and TRIO Trials	Watch now
TCT 2021 – RADIANCE-HTN TRIO 6 months Outcomes vs Sham Procedure for Resistant Hypertension	Watch now
ACC 2021 – RADIANCE-HTN TRIO Trial Results with Ajay Kirtane	Watch now
EuroPCR 2020 – Crossover Results From the RADIANCE-HTN SOLO Trial	Watch now

Part 6

Patient Perspective & Provider Referral Development

Understand patient preference and referral development

1 session
Ultrasound Renal Denervation – Patient Perspective, Referral Development	Watch now

Part 7

Discussion With Experts

2 sessions
ACC 2022 Symposium	Watch now
TCT 2021 Symposium	Watch now

Faculty Biographies

Melvin D Lobo

Professor Melvin Lobo is a Consultant Physician based in St Bartholomew’s Hospital and the William Harvey Research Institute. He has a specialist interest in blood pressure disorders of all types, autonomic control of the circulation and also resistant hypertension and device-based therapies.

View full profile